GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (LTS:0EVI) » Definitions » Net Interest Income (for Banks)

Innate Pharma (LTS:0EVI) Net Interest Income (for Banks)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Innate Pharma Business Description

Industry
Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.